Comparative Pharmacology
Head-to-head clinical analysis: LOSARTAN POTASSIUM versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOSARTAN POTASSIUM versus TEVETEN HCT.
LOSARTAN POTASSIUM vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II receptor antagonist. Blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, resulting in vasodilation and reduced aldosterone secretion.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Terminal elimination half-life: losartan ~2 hours; active metabolite E-3174 ~6-9 hours. Clinically, the long half-life of E-3174 allows once-daily dosing.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Losartan and its active metabolite E-3174 are eliminated via renal (35% of dose) and biliary/fecal (60% of dose) routes. Approximately 4% of an oral dose is excreted unchanged in urine, while 6% is excreted as E-3174 in urine.
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination